DDInter1605 DDInter927
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Risperidone {u} (Compound) resembles {v} (Compound) Dapiprazole
Risperidone {u} (Compound) binds {v} (Gene) ADRA1B
Risperidone {u} (Compound) upregulates {v} (Gene) UBQLN2
Risperidone {u} (Compound) palliates {v} (Disease) schizophrenia
Risperidone {u} (Compound) downregulates {v} (Gene) ACAT2
Risperidone {u} (Compound) causes {v} (Side Effect) Manic psychosis
Risperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Risperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Risperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipratropium
Risperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Histrelin
Risperidone (Compound) resembles Dapiprazole (Compound)
Risperidone (Compound) binds ADRA1B (Gene)
Risperidone (Compound) upregulates UBQLN2 (Gene)
Risperidone (Compound) palliates schizophrenia (Disease)
Risperidone (Compound) downregulates ACAT2 (Gene)
Risperidone (Compound) causes Manic psychosis (Side Effect)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Risperidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin